Home > Oncology > ESMO 2021 > Melanoma > Adjuvant immunotherapy reduces risk of disease recurrence in stage II melanoma

Adjuvant immunotherapy reduces risk of disease recurrence in stage II melanoma

Presented By
Dr Jason Luke, UPMC Hillman Cancer Center, PA, USA
Conference
ESMO 2021
Trial
Phase 3, KEYNOTE-716
The first interim analysis of KEYNOTE-716 suggests adjuvant pembrolizumab to be superior to standard-of-care observation for adult and children with completely resected high-risk melanoma. Patients with stage IIB-C melanoma are at high risk of disease recurrence and survival outcomes are similar to stage IIIA-B melanoma [1]. In patients with stage III melanoma, adjuvant therapy with pembrolizumab prolonged recurrence-free survival (RFS) as well as distant metastasis-free survival (DMFS) [2]. The phase 3, double-blind KEYNOTE-716 trial (NCT03553836) evaluated pembrolizumab versus placebo in patients with resected stage IIB or IIC melanoma. Dr Jason Luke (UPMC Hillman Cancer Center, PA, USA) presented results from the first interim analysis of KEYNOTE-716 [3]. A total of 976 patients (64% stage IIB, 34.8% stage IIC; aged ≥12 years with complete resection of cu...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on